These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 34093179)

  • 41. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
    Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines.
    Arellano AL; Papaseit E; Romaguera A; Torrens M; Farré M
    CNS Neurol Disord Drug Targets; 2017; 16(5):554-566. PubMed ID: 28412920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.
    Renard J; Loureiro M; Rosen LG; Zunder J; de Oliveira C; Schmid S; Rushlow WJ; Laviolette SR
    J Neurosci; 2016 May; 36(18):5160-9. PubMed ID: 27147666
    [TBL] [Abstract][Full Text] [Related]  

  • 45. From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?
    Lippiello P; Balestrini S; Leo A; Coppola A; Citraro R; Elia M; Russo E; De Sarro G
    Curr Pharm Des; 2016; 22(42):6426-6433. PubMed ID: 27587196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Impact of Cannabidiol on Psychiatric and Medical Conditions.
    Oberbarnscheidt T; Miller NS
    J Clin Med Res; 2020 Jul; 12(7):393-403. PubMed ID: 32655732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.
    Hayakawa K; Mishima K; Fujiwara M
    Pharmaceuticals (Basel); 2010 Jul; 3(7):2197-2212. PubMed ID: 27713349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.
    Campos AC; Ortega Z; Palazuelos J; Fogaça MV; Aguiar DC; Díaz-Alonso J; Ortega-Gutiérrez S; Vázquez-Villa H; Moreira FA; Guzmán M; Galve-Roperh I; Guimarães FS
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1407-19. PubMed ID: 23298518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The therapeutic potential of purified cannabidiol.
    O'Sullivan SE; Jensen SS; Nikolajsen GN; Bruun HZ; Bhuller R; Hoeng J
    J Cannabis Res; 2023 Jun; 5(1):21. PubMed ID: 37312194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
    Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
    Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.
    Rodríguez-Muñoz M; Onetti Y; Cortés-Montero E; Garzón J; Sánchez-Blázquez P
    Mol Brain; 2018 Sep; 11(1):51. PubMed ID: 30223868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.
    Osborne AL; Solowij N; Babic I; Lum JS; Huang XF; Newell KA; Weston-Green K
    Brain Behav Immun; 2019 Oct; 81():574-587. PubMed ID: 31326506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
    Hahn B
    Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.
    Nona CN; Hendershot CS; Le Foll B
    Exp Clin Psychopharmacol; 2019 Aug; 27(4):359-369. PubMed ID: 31120285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cannabis sativa: Much more beyond Δ
    Alves P; Amaral C; Teixeira N; Correia-da-Silva G
    Pharmacol Res; 2020 Jul; 157():104822. PubMed ID: 32335286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels.
    Sales AJ; Crestani CC; Guimarães FS; Joca SRL
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():255-261. PubMed ID: 29885468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling.
    Fogaça MV; Campos AC; Coelho LD; Duman RS; Guimarães FS
    Neuropharmacology; 2018 Jun; 135():22-33. PubMed ID: 29510186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.